T. King, Author at Compliance Insight - Page 2 of 6

Medical-Devices-scaled

March 6, 2025by T. King

Key Requirements for Importing Medical Devices

March 3, 2025by T. King

How to Prepare for an FDA Audit and Avoid Common Pitfalls

August 16, 2024by T. King

How AI is Revolutionizing Medical Diagnostics!

Warning Letter

August 14, 2024by T. King

Understanding the Critical Differences

August 12, 2024by T. King

Understanding the Implications of Delays, Denials, and Limitations on FDA Inspections

August 8, 2024by T. King

FDA Mock Audit vs. FDA cGMP Audit

August 6, 2024by T. King

User Fees FY 2025

July 24, 2024by T. King

Preparing for the Future of LDTs

July 22, 2024by T. King

Tests Outside the Phaseout Approach

July 17, 2024by T. King

FDA Guidance on Application User Fees for Combination Products (2024)

July 17, 2024by T. King

Phaseout Approach for LDT Rule Implementation

July 15, 2024by T. King

Impact on Research Use Only (RUO) Manufacturers

July 11, 2024by T. King

Impact on IVD Manufacturers

July 10, 2024by T. King

LDT’s Detailed Impact on CLIA Labs

June 27, 2024by T. King

Understanding the New Landscape for Lab Developed Tests

June 18, 2024by T. King

Navigating the New MoCRA Act for Cosmetic Companies

June 12, 2024by T. King

A Golden Opportunity for Cosmetics Professionals: Navigating MoCRA with Ease

May 9, 2024by T. King

Advancing Healthcare with Laboratory Developed Tests (LDTs): Specific Applications and Future Directions

May 7, 2024by T. King

Introduction to Laboratory Developed Tests (LDTs) and Their Regulatory Landscape

May 3, 2024by T. King

Understanding FDA’s Role in Emergency Health Responses

May 1, 2024by T. King

Understanding the FDA’s New Guidance on Immediate Response Tests

Top